Mark I. Evans

1.2k total citations
33 papers, 730 citations indexed

About

Mark I. Evans is a scholar working on Pediatrics, Perinatology and Child Health, Surgery and Urology. According to data from OpenAlex, Mark I. Evans has authored 33 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pediatrics, Perinatology and Child Health, 6 papers in Surgery and 6 papers in Urology. Recurrent topics in Mark I. Evans's work include Prenatal Screening and Diagnostics (17 papers), Urological Disorders and Treatments (6 papers) and Congenital Anomalies and Fetal Surgery (5 papers). Mark I. Evans is often cited by papers focused on Prenatal Screening and Diagnostics (17 papers), Urological Disorders and Treatments (6 papers) and Congenital Anomalies and Fetal Surgery (5 papers). Mark I. Evans collaborates with scholars based in United States, United Kingdom and Israel. Mark I. Evans's co-authors include Mark P. Johnson, Mark P. Johnson, Andrew L. Freedman, Ricardo González, Craig A. Smith, Peter G. Pryde, Timothy P. Bukowski, Nelson B. Isada, David Krantz and John C. Fletcher and has published in prestigious journals such as The Lancet, American Journal of Obstetrics and Gynecology and American Journal of Medical Genetics.

In The Last Decade

Mark I. Evans

33 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark I. Evans United States 15 535 236 219 117 80 33 730
J. Offermans Netherlands 11 223 0.4× 94 0.4× 160 0.7× 56 0.5× 86 1.1× 25 559
Annette Queißer‐Luft Germany 11 342 0.6× 120 0.5× 203 0.9× 122 1.0× 74 0.9× 19 658
Mark P. Johnson United States 10 337 0.6× 121 0.5× 128 0.6× 61 0.5× 28 0.3× 13 441
Mark I. Evans United States 11 295 0.6× 109 0.5× 127 0.6× 43 0.4× 44 0.6× 11 450
Jack Fitzsimmons United States 17 396 0.7× 112 0.5× 236 1.1× 73 0.6× 156 1.9× 35 701
C. De Vigan France 15 450 0.8× 50 0.2× 262 1.2× 50 0.4× 54 0.7× 27 797
Ralph L. Kramer United States 15 513 1.0× 42 0.2× 129 0.6× 56 0.5× 267 3.3× 35 728
Edith L. Pøtter United States 12 401 0.7× 178 0.8× 173 0.8× 319 2.7× 98 1.2× 38 864
Joaquín E. Paz Brazil 13 161 0.3× 85 0.4× 261 1.2× 124 1.1× 28 0.3× 24 590
Giovanni Monni Italy 18 794 1.5× 32 0.1× 315 1.4× 76 0.6× 93 1.2× 75 1.2k

Countries citing papers authored by Mark I. Evans

Since Specialization
Citations

This map shows the geographic impact of Mark I. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark I. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark I. Evans more than expected).

Fields of papers citing papers by Mark I. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark I. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark I. Evans. The network helps show where Mark I. Evans may publish in the future.

Co-authorship network of co-authors of Mark I. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Mark I. Evans. A scholar is included among the top collaborators of Mark I. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark I. Evans. Mark I. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Evans, Mark I., Harold H. Harrison, Joseph E. O’Brien, et al.. (2002). Correction for insulin-dependent diabetes in maternal serum α-fetoprotein testing has outlived its usefulness. American Journal of Obstetrics and Gynecology. 187(4). 1084–1086. 10 indexed citations
2.
Pryde, Peter G., Mordechai Hallak, Michele R. Lauria, et al.. (2000). Severe Oligohydramnios with Intact Membranes: An Indication for Diagnostic Amnioinfusion. Fetal Diagnosis and Therapy. 15(1). 46–49. 13 indexed citations
3.
Freedman, Andrew L., Mark P. Johnson, Craig A. Smith, Ricardo González, & Mark I. Evans. (1999). Long-term outcome in children after antenatal intervention for obstructive uropathies. The Lancet. 354(9176). 374–377. 140 indexed citations
4.
Evans, Mark I., Joseph E. O’Brien, & Anthony Johnson. (1999). Screening for aneuploidy. Current Opinion in Obstetrics & Gynecology. 11(2). 115–118. 2 indexed citations
5.
Kramer, Ralph L., et al.. (1998). Determinants of parental decisions after the prenatal diagnosis of Down syndrome. American Journal of Medical Genetics. 79(3). 172–174. 46 indexed citations
6.
Yaron, Yuval, et al.. (1998). Pastoral Care Utilization among Women Electing Pregnancy Termination for Fetal Anomalies. Fetal Diagnosis and Therapy. 13(2). 123–126. 1 indexed citations
7.
Sokol, Andrew I., Ralph L. Kramer, Yuval Yaron, et al.. (1998). Age-specific variation in aneuploidy incidence among biochemical screening programs. American Journal of Obstetrics and Gynecology. 179(4). 971–973. 8 indexed citations
8.
Hume, Roderick F., Laura Martin, Sidney F. Bottoms, et al.. (1997). Vascular Disruption Birth Defects and History of Prenatal Cocaine Exposure: A Case Control Study. Fetal Diagnosis and Therapy. 12(5). 292–295. 23 indexed citations
9.
Qureshi, Faisal, Suzanne M. Jacques, Mark P. Johnson, et al.. (1997). Trisomy 21 Placentas: Histopathological and Immunohistochemical Findings using Proliferating Cell Nuclear Antigen. Fetal Diagnosis and Therapy. 12(4). 210–215. 32 indexed citations
10.
Johnson, Mark P., et al.. (1996). Abnormal Biochemical Serum Screening versus 2nd-Trimester Ultrasound-Detected Minor Anomalies as Predictors of Aneuploidy in Low-Risk Patients. Fetal Diagnosis and Therapy. 11(5). 301–305. 13 indexed citations
11.
Tomlinson, Mark W., Mark P. Johnson, Mary Etta King, et al.. (1996). Correction of Hemodynamic Abnormalities by Vesicoamniotic Shunting in Familial Congenital Megacystis. Fetal Diagnosis and Therapy. 11(1). 46–49. 5 indexed citations
12.
Tafas, Triantafyllos, et al.. (1996). An Automated Image Analysis Method for the Measurement of Neutrophil Alkaline Phosphatase in the Prenatal Screening of Down Syndrome. Fetal Diagnosis and Therapy. 11(4). 254–259. 7 indexed citations
13.
Qureshi, Faisal, Suzanne M. Jacques, Brian Seifman, et al.. (1996). In utero Fetal Urine Analysis and Renal Histology Correlate with the Outcome in Fetal Obstructive Uropathies. Fetal Diagnosis and Therapy. 11(5). 306–312. 29 indexed citations
14.
Quintero, Rubén A. & Mark I. Evans. (1995). Bringing surgery to the fetus. The Lancet. 346. S18–S18. 1 indexed citations
15.
Ebrahim, Salah, et al.. (1995). Prenatal cytogenetic abnormalities: Correlations of structural rearrangements and ultrasonographically detected fetal anomalies. American Journal of Obstetrics and Gynecology. 173(4). 1334–1336. 14 indexed citations
16.
Johnson, Mark P., et al.. (1994). In utero surgical treatment of fetal obstructive uropathy: A new comprehensive approach to identify appropriate candidates for vesicoamniotic shunt therapy. American Journal of Obstetrics and Gynecology. 170(6). 1770–1779. 147 indexed citations
17.
Isada, Nelson B., et al.. (1993). Amniotic Fluid Acetylcholinesterase Is Found in Gastroschisis but Not Omphalocele. Fetal Diagnosis and Therapy. 8(3). 168–170. 3 indexed citations
18.
Johnson, Mark P., et al.. (1990). Postmortem chorionic villus sampling is a better method for cytogenetic evaluation of early fetal loss than culture of abortus material. American Journal of Obstetrics and Gynecology. 163(5). 1505–1510. 20 indexed citations
19.
20.
Evans, Mark I., Ivan E. Zador, Faisal Qureshi, et al.. (1988). Ultrasonographic prenatal diagnosis and fetal pathology of Langer mesomelic dwarfism. American Journal of Medical Genetics. 31(4). 915–920. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Offermans Breakdown of academic impact, for papers by Annette Queißer‐Luft Breakdown of academic impact, for papers by Mark P. Johnson Breakdown of academic impact, for papers by Mark I. Evans Breakdown of academic impact, for papers by Jack Fitzsimmons Breakdown of academic impact, for papers by C. De Vigan Breakdown of academic impact, for papers by Ralph L. Kramer Breakdown of academic impact, for papers by Edith L. Pøtter Breakdown of academic impact, for papers by Joaquín E. Paz Breakdown of academic impact, for papers by Giovanni Monni
Rankless by CCL
2026